Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5935356 | 0.83 | HRH3 (0.87) | HRH3KDM4EDRD2MAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL5935407 | 0.82 | HRH3 (0.73) | HRH3KDM4EDRD2MAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL5935440 | 0.82 | KDM4E (0.61) | HRH3KDM4EDRD2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5935441 | 0.82 | KDM4E (0.61) | HRH3KDM4EDRD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4089542 | 0.81 | HRH3 (0.97) | HRH3DRD2ALDH1A1HPGDMEN1 | |
| SCHEMBL3586400 | 0.80 | HRH3 (0.68) | HRH3ALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL5935368 | 0.80 | HRH3 (0.72) | HRH3KDM4EDRD2MAOBALDH1A1 | |
| SCHEMBL4084267 | 0.79 | HRH3 (0.72) | HRH3KDM4EDRD2ALDH1A1HPGD | |
| SCHEMBL12050654 | 0.79 | HRH3 (0.72) | HRH3KDM4EDRD2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL5935367 | 0.79 | HRH3 (0.79) | HRH3KDM4EDRD2MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | BEST DESMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1554260-A1 | ARYLOXYALKYLAMINE DERIVATIVES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | HRH3, HTR6, HTR4 | HRH3 1/4885KDM4E 563/4885DRD2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.